CNS Drugs

, Volume 17, Issue 7, pp 491–511 | Cite as

Suicidal Behaviour in Bipolar Disorder

Risk and Prevention
  • Leonardo TondoEmail author
  • Göran Isacsson
  • Ross J. Baldessarini
Therapy in Practice


Bipolar (manic-depressive) disorder is a common and severe illness. It is also potentially fatal as a result of accidents and increased mortality associated with comorbid substance use and medical illnesses, but its highest lethality results from suicide. Suicide rates, averaging 0.4% per year in men and women diagnosed with bipolar disorder, are >20-fold higher than in the general population. Suicidal acts often occur early in the illness course and in association with severe depressive and dysphoric-agitated mixed phases of illness, especially following repeated, severe depressions.

Systematic consideration of risk and protective factors enhances assessment of potentially suicidal patients. Short-term interventions employed empirically to manage acute suicidality include close clinical supervision, rapid hospitalisation and use of electroconvulsive treatment. Several plausible therapeutic interventions have limited evidence of long-term effectiveness against mortality risks associated with any psychiatric disorder, including antidepressant, antimanic, antipsychotic and electroconvulsive, as well as psychosocial, treatments. However, in bipolar disorder and other major affective disorders, lithium maintenance treatment is a notable exception, with strong and consistent evidence that it reduces suicidal risk.

The growing range of drugs being introduced to treat acute and long-term phases of bipolar disorder, including antiepileptic drugs, atypical antipsychotics and relatively safe, modern antidepressants, require research assessment for their ability to limit premature mortality from suicide and other causes. For now, however, more can be done to improve treatment in major affective illnesses by application of current knowledge in a systematic fashion, with close and sustained clinical follow-up of patients at risk, hopefully with a resulting reduction of mortality rates.


Bipolar Disorder Clozapine Suicide Attempt Suicidal Behaviour Suicide Rate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Supported, in part, by a Stanley Medical Research Institute award, a NARSAD Investigator award (Dr Tondo), an award from the Bruce J. Anderson Foundation and the McLean Private Donors Neuropsychopharmacology Research Fund (to Dr Baldessarini). Mr Matthew Albert provided valuable bibliographical assistance.

Dr Baldessarini has professional relationships (consulting agreements or research support) with the following corporations: Auritec Labs, Biostream Labs, Eli Lilly Labs (Indianapolis), GlaxoSmithKline Corp, IFI SpA, Janssen Pharmaceuticals, Protarga Corp and Solvay Corp. Dr Tondo has professional relationships (consulting agreement) with IFI SpA, Rome.


  1. 1.
    Regier DA, Myers JK, Kramer M, et al. The NIMH Epidemiologic Catchment Area program: historical context, major objectives, and study population characteristics. Arch Gen Psychiatry 1984; 41: 934–41PubMedCrossRefGoogle Scholar
  2. 2.
    Goodwin FK, Jamison KR. Manic-depressive illness. New York: Oxford University Press, 1990Google Scholar
  3. 3.
    Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51: 8–19PubMedCrossRefGoogle Scholar
  4. 4.
    Institute of Medicine. Reducing suicide. Washington, DC: The National Academics Press, 2002: 69–75Google Scholar
  5. 5.
    Tohen M, Angst J. Epidemiology of bipolar disorder. In:Tsuang MT, Tohen M, editors. Textbook in psychiatric epidemiology. 2nd ed. New York: John Wiley & Sons, 2002: 427–44CrossRefGoogle Scholar
  6. 6.
    Angst J. The emerging epidemiology of hypomania and bipolar II disorder. J Affect Disord 1998; 50: 143–51PubMedCrossRefGoogle Scholar
  7. 7.
    Akiskal HS, Bourgeois ML, Angst J, et al. Re-evaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders. J Affect Disord 2000; 59Suppl. 1: 5–30CrossRefGoogle Scholar
  8. 8.
    Baldessarini RJ. Drugs and the treatment of psychiatric disorders: antidepressant and antianxiety agents. In: Hardman JG, Limbird LE, Gilman AG, editors. Goodman and Gilman’s the pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill, 2001: 447–83Google Scholar
  9. 9.
    Baldessarini RJ, Tarazi FI. Drugs and the treatment of psychiatric disorders: antipsychotic and antimanic agents. In: Hardman JG, Limbird LE, Gilman AG, editors. Goodman and Gilman’s the pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill, 2001: 485–520Google Scholar
  10. 10.
    Hirschfeld RMA, Bowden CL, Gitlin MJ, et al., editors. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002; 159(4 Suppl.): 1–50Google Scholar
  11. 11.
    Baldessarini RJ, Jamison KR, editors. Effects of medical interventions on suicidal behavior. J Clin Psychiatry 1999; 60(2 Suppl.): 1–122Google Scholar
  12. 12.
    Angst J, Sellaro R, Angst F. Long-term outcome and mortality of treated vs untreated bipolar and depressed patients: a preliminary report. Int J Psychiatr Clin Pract 1998; 2: 115–9CrossRefGoogle Scholar
  13. 13.
    Isacsson G. Suicide prevention: a medical breakthrough? Acta Psychiatr Scand 2000; 102: 113–7PubMedCrossRefGoogle Scholar
  14. 14.
    Tondo L, Baldessarini RJ. Reduced suicide risk during lithium maintenance treatment. J Clin Psychiatry 2000; 61Suppl. 9: 97–104PubMedGoogle Scholar
  15. 15.
    Khan A, Warner HA, Brown WA. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the FDA database. Arch Gen Psychiatry 2000; 57: 311–7PubMedCrossRefGoogle Scholar
  16. 16.
    Zimmerman M, Mattia JI, Posternak MA. Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice? Am J Psychiatry 2002; 159: 469–73PubMedCrossRefGoogle Scholar
  17. 17.
    Robins E, Murphy GE, Wilkinson RH, et al. Some clinical considerations in the prevention of suicide based on a study of 134 successful suicides. Am J Public Health 1959; 49: 888–99CrossRefGoogle Scholar
  18. 18.
    Cheng ATA. Mental illness and suicide. Arch Gen Psychiatry 1995; 52: 594–603PubMedCrossRefGoogle Scholar
  19. 19.
    Tanney BL. Psychiatric diagnoses and suicidal acts. In: Maris RW, Berman AL, Silverman MM, editors. Comprehensive textbook of suicidology. New York: Guilford Press 2000: 311–41Google Scholar
  20. 20.
    Barraclough B, Bunch J, Nelson B, et al. A hundred cases of suicide: clinical aspects. Br J Psychiatry 1974; 125: 355–73PubMedCrossRefGoogle Scholar
  21. 21.
    Isometsä ET, Henriksson MM, Aro HM, et al. Suicide in bipolar disorder in Finland. Am J Psychiatry 1994; 151: 1020–4PubMedGoogle Scholar
  22. 22.
    Arató M, Demeter E, Rihmer Z, et al. Retrospective psychiatric assessment of 200 suicides in Budapest. Acta Psychiatr Scand 1988; 77: 454–6PubMedCrossRefGoogle Scholar
  23. 23.
    American Association of Suicidology (AAS). Official 1998 statistics [online]. Available from URL: [Accessed 2000 Oct 24]
  24. 24.
    World Health Organization (WHO). Most recent data available, 2001 Oct [online]. Available from URL: [Accessed 2001 Oct 30]
  25. 25.
    Mäkinen IH, Wasserman D. Suicide prevention and cultural resistance: stability in suicide ranking of European countries, 1970–88. Ital J Suicidology 1997; 7: 73–85Google Scholar
  26. 26.
    Harris EC, Barraclough B. Suicide as an outcome for mental disorders: a meta-analysis. Br J Psychiatry 1997; 170: 205–8PubMedCrossRefGoogle Scholar
  27. 27.
    Kay DWK, Petterson U. Manic-depressive illness. Acta Psychiatr Scand 1977; 54Suppl. 269: 55–60CrossRefGoogle Scholar
  28. 28.
    Dunner DL, Gershon ES, Goodwin FK. Heritable factors in the severity of affective illness. Biol Psychiatry 1976; 11: 31–42PubMedGoogle Scholar
  29. 29.
    Tondo L, Baldessarini RJ. Suicide: an overview [online]. Available from URL: [Accessed 29 April 2003]
  30. 30.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. Washington, DC: American Psychiatric Association, 1980Google Scholar
  31. 31.
    International classification of diseases. 9th ed. Geneva: World Health Organization, 1975Google Scholar
  32. 32.
    Guze SB, Robins E. Suicide and primary affective disorders. Br J Psychiatry 1970; 117: 437–8PubMedCrossRefGoogle Scholar
  33. 33.
    Inskip HM, Harris EC, Barraclough B. Lifetime risk of suicide for affective disorder, alcoholism and schizophrenia. Br J Psychiatry 1998; 172: 35–7PubMedCrossRefGoogle Scholar
  34. 34.
    Blair-West GW, Cantor CH, Mellsop GW, et al. Lifetime suicide risk in major depression: sex and age determinants. J Affect Disord 1999; 55: 171–8PubMedCrossRefGoogle Scholar
  35. 35.
    Bostwick JM, Pankratz VS. Affective disorders and suicide risk: a re-examination. Am J Psychiatry 2000; 157: 1925–32PubMedCrossRefGoogle Scholar
  36. 36.
    O’Leary D, Paykel E, Todd C, et al. Suicide in primary affective disorders revisited: a systematic review by treatment era. J Clin Psychiatry 2001; 62: 804–11PubMedCrossRefGoogle Scholar
  37. 37.
    Lundquist G. Prognosis and course in manic-depressive psychoses. Acta Psychiatr Scand 1945; Suppl. 35: 1–96Google Scholar
  38. 38.
    Hastings DW. Follow-up results in psychiatric illness. Am J Psychiatry 1958; 114: 1058–66Google Scholar
  39. 39.
    Perris C, D’Elia G. A study of bipolar (manic-depressive) and unipolar recurrent depressive psychoses. Acta Psychiatr Scand 1966; 42Suppl. 194: 172–89CrossRefGoogle Scholar
  40. 40.
    Bratfos O, Haug JP. The course of manic-depressive psychosis. Acta Psychiatr Scand 1968; 44: 89–112PubMedCrossRefGoogle Scholar
  41. 41.
    Carlson GA, Kotin J, Davenport YB, et al. Follow-up of 53 manic-depressive patients. Br J Psychiatry 1974; 124: 134–9PubMedCrossRefGoogle Scholar
  42. 42.
    Noriek K. Attempted suicide and suicide in functional psychoses. Acta Psychiatr Scand 1975; 52: 81–106CrossRefGoogle Scholar
  43. 43.
    Tsuang MT. Suicide in schizophrenics, manics, depressives, and surgical controls. Arch Gen Psychiatry 1978; 35: 153–5PubMedCrossRefGoogle Scholar
  44. 44.
    Morrison JR. Suicide in a psychiatric practice population. J Clin Psychiatry 1982; 43: 348–52PubMedGoogle Scholar
  45. 45.
    Martin RL, Cloninger R, Guze SB, et al. Mortality in a follow-up of 500 psychiatric patients. Arch Gen Psychiatry 1985; 42: 58–66PubMedCrossRefGoogle Scholar
  46. 46.
    Weeke A, Vaeth M. Excess mortality of bipolar and unipolar manic-depressive patients. J Affect Disord 1986; 11: 227–34PubMedCrossRefGoogle Scholar
  47. 47.
    Black DW, Winokur G, Nasrallah A. Effect of psychosis on suicide risk in 1593 patients with unipolar and bipolar affective disorders. Am J Psychiatry 1988; 145: 849–52PubMedGoogle Scholar
  48. 48.
    Dingman CW, McGlashan TH. Characteristics of patients with serious suicidal intentions who ultimately commit suicide. Hosp Community Psychiatry 1988; 39: 295–9PubMedGoogle Scholar
  49. 49.
    Friis S, Hauff E, Island TK, et al. The Ullevål acute ward follow-up study: a personal 7-year follow-up of patients with functional psychosis admitted to the acute ward of a catchment area. Psychopathology 1991; 24: 316–27PubMedCrossRefGoogle Scholar
  50. 50.
    Newman S, Bland R. Suicide risk varies by subtype of affective disorder. Acta Psychiatr Scand 1991; 83: 420–6PubMedCrossRefGoogle Scholar
  51. 51.
    Sharma R, Markar HR. Mortality in affective disorder. J Affect Disord 1994; 31: 91–6PubMedCrossRefGoogle Scholar
  52. 52.
    Koukopoulos A, Reginaldi D, Minnai G, et al. The long-term prophylaxis of affective disorders. In: Gessa G, Fratta W, Pani L, editors. Depression and mania: from neurobiology to treatment. New York: Raven Press, 1995: 127–47Google Scholar
  53. 53.
    Thies-Flechtner K, Muller-Oerlinghausen B, Seibert W, et al. Effect of prophylactic treatment on suicide risk in patients with major affective disorders: data from a randomized prospective trial. Pharmacopsychiatry 1996; 29: 103–7PubMedCrossRefGoogle Scholar
  54. 54.
    Angst J, Sellaro R, Angst F. Long-term outcome and mortality of treated vs untreated bipolar and depressed patients: a preliminary report. Int J Psychiatr Clin Pract 1998; 2: 115–9CrossRefGoogle Scholar
  55. 55.
    Bocchetta A, Ardau R, Burrai C, et al. Suicidal behavior on and off lithium prophylaxis in a group of patients with prior suicide attempts. J Clin Psychopharmacol 1998; 18: 384–9PubMedCrossRefGoogle Scholar
  56. 56.
    Tondo L, Baldessarini RJ, Hennen J, et al. Lithium treatment and risk of suicidal behavior in bipolar disorder patients. J Clin Psychiatry 1998; 59: 405–14PubMedCrossRefGoogle Scholar
  57. 57.
    Brodersen A, Licht RW, Vestergaard P, et al. Sixteen-year mortality in patients with affective disorder commenced on lithium. Br J Psychiatry 2000; 176: 419–33CrossRefGoogle Scholar
  58. 58.
    Høyer E, Mortensen P, Olesen A. Mortality and causes of death in a total national sample of patients with affective disorders admitted for the first time between 1973 and 1993. Br J Psychiatry 2000; 176: 76–82PubMedCrossRefGoogle Scholar
  59. 59.
    Kallner G, Lindelius R, Petterson U, et al. Mortality in 497 patients with affective disorders attending a lithium clinic or after having left it. Pharmacopsychiatry 2000; 33: 8–13PubMedCrossRefGoogle Scholar
  60. 60.
    Kleindienst N, Greil W. Differential efficacy of lithium and carbamazepine in the prophylaxis of bipolar disorder: results of the MAP study. Neuropsychobiology 2000; 42: 2–10PubMedCrossRefGoogle Scholar
  61. 61.
    Gladstone LG, Mitchell PB, Parker G, et al. Indicators of suicide over 10 years in a specialist mood disorder unit sample. J Clin Psychiatry 2001; 62: 945–51PubMedCrossRefGoogle Scholar
  62. 62.
    Ösby U, Brandt L, Correia N, et al. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry 2001; 58: 844–50PubMedCrossRefGoogle Scholar
  63. 63.
    Lester D. Suicidal behavior in bipolar and unipolar affective disorders: a meta-analysis. J Affect Disord 1993; 27: 117–21PubMedCrossRefGoogle Scholar
  64. 64.
    Rihmer Z, Pestality P. Bipolar II disorder and suicidal behavior. Psychiatr Clin North Am 1999; 22: 667–73PubMedCrossRefGoogle Scholar
  65. 65.
    Bottlender R, Jager M, Strauss A, et al. Suicidality in bipolar compared to unipolar depressed inpatients. Eur Arch Psychiatry Clin Neurosci 2000; 250: 257–61PubMedCrossRefGoogle Scholar
  66. 66.
    Ahrens B, Müller-Oerlinghausen B, Schou M, et al. Excess cardiovascular and suicide mortality of affective disorders may be reduced by lithium prophylaxis. J Affect Disord 1995; 33: 67–75PubMedCrossRefGoogle Scholar
  67. 67.
    Móscicki EK. Epidemiology of completed and attempted suicide: toward a framework for prevention. Clin Neurosci Res 2001; 1: 310–23CrossRefGoogle Scholar
  68. 68.
    Dilsaver SC, Chen Y-W, Swann AC, et al. Suicidality, panic disorder and psychosis in bipolar depression, depressive-mania and pure mania. Psychiatry Res 1997; 73: 47–56PubMedCrossRefGoogle Scholar
  69. 69.
    Hirschfeld RMA, Davidson L. Clinical risk factors for suicide. Psychiatr Ann 1988; 18: 628–35Google Scholar
  70. 70.
    Jacobs DG, Brewer M, Klein-Benheim M. Suicide assessment: an overview and recommended protocol. In: Jacobs DG, editor. Harvard Medical School guide to assessment and intervention in suicide. San Francisco (CA): Jossey-Bass, 1998: 3–39Google Scholar
  71. 71.
    Sachs GS, Yan LJ, Swann AC, et al. Integration of suicide prevention into outpatient management of bipolar disorder. J Clin Psychiatry 2001; 62Suppl. 25: 3–11PubMedGoogle Scholar
  72. 72.
    Frances RJ, Franklin J, Flavin DK. Suicide and alcoholism. Am J Drug Alcohol Abuse 1987; 13: 327–41PubMedCrossRefGoogle Scholar
  73. 73.
    Móscicki EK. Identification of suicide risk factors using epidemiologic studies. Psychiatr Clin North Am 1997; 20: 499–517PubMedCrossRefGoogle Scholar
  74. 74.
    Strakowski SM, Del Bello MP, Flex DE, et al. The impact of substance abuse on the course of bipolar disorder. Biol Psychiatry 2000; 48: 477–85PubMedCrossRefGoogle Scholar
  75. 75.
    Tondo L, Baldessarini RJ, Hennen J, et al. Suicide attempts in major affective disorder patients with comorbid substance use disorders. J Clin Psychiatry 1999; 60Suppl. 2: 63–9PubMedGoogle Scholar
  76. 76.
    Nierenberg AA, Gray SM, Grandin LD. Mood disorders and suicide. J Clin Psychiatry 2001; 62Suppl. 25: 27–30PubMedGoogle Scholar
  77. 77.
    Fawcett J. Suicide assessment: an overview and recommended protocol. In: Jacobs DG, editor. Harvard Medical School guide to assessment and intervention in suicide. San Francisco (CA): Jossey-Bass, 1998: 115–24Google Scholar
  78. 78.
    Mann JJ, Waternaux C, Haas GL, et al. Toward a clinical model of suicidal behavior in psychiatric patients. Am J Psychiatry 1999; 156: 181–9PubMedGoogle Scholar
  79. 79.
    Corruble E, Damy C, Guelfi JD. Impulsivity: a relevant dimension in depression regarding suicide attempts? J Affect Disord 1999; 53: 211–5PubMedCrossRefGoogle Scholar
  80. 80.
    Goldberg JF, Singer TM, Garno JL. Suicidality and substance abuse in affective disorders. J Clin Psychiatry 2001; 62Suppl. 25: 35–43PubMedGoogle Scholar
  81. 81.
    Baca-García E, Diaz-Sastre C, Basurte E, et al. A prospective study of the paradoxical relationship between impulsivity and lethality of suicide attempts. J Clin Psychiatry 2001; 62: 560–4PubMedCrossRefGoogle Scholar
  82. 82.
    Wu LH, Dunner DL. Suicide attempts in rapid cycling bipolar disorder patients. J Affect Disord 1993; 29: 57–61PubMedCrossRefGoogle Scholar
  83. 83.
    Goodwin FK. Anticonvulsant therapy and suicide in affective disorders. J Clin Psychiatry 1999; 60Suppl. 2: 89–93PubMedGoogle Scholar
  84. 84.
    Wender PH, Kety SS, Rosenthal D, et al. Psychiatric disorders in the biological and adoptive families of adopted individuals with affective disorders. Arch Gen Psychiatry 1986; 43: 923–9PubMedCrossRefGoogle Scholar
  85. 85.
    Turecki G. Suicidal behavior: is there a genetic predisposition? Bipolar Disord 2001; 3: 335–49PubMedCrossRefGoogle Scholar
  86. 86.
    Conwell Y, Henderson RE. Neuropsychiatry of suicide. In: Fogel BS, Schiffer RB, Rao SM, editors. Neuropsychiatry. Baltimore (MD): Williams & Wilkins, 1996: 485–521Google Scholar
  87. 87.
    Holmes TH, Rahe RH. The social readjustment rating scale. J Psychosom Res 1967; 11: 213–8PubMedCrossRefGoogle Scholar
  88. 88.
    Rich CL, Warsradt GM, Nemiroff RA, et al. Suicide, stressors, and the life cycle. Am J Psychiatry 1991; 148: 524–6PubMedGoogle Scholar
  89. 89.
    Minois G. History of suicide: voluntary death, in western culture. Baltimore (MD): Johns Hopkins University Press, 1999Google Scholar
  90. 90.
    Tondo L. Prima del tempo. Rome: Carocci, 2000Google Scholar
  91. 91.
    Shneidman ES. Suicide, lethality, and the psychological autopsy. Int Psychiatry Clin 1969; 6: 225–50PubMedGoogle Scholar
  92. 92.
    Beck AT, Beck R, Kovacs M. Classification of suicidal behaviors: quantifying intent and medical lethality. Am J Psychiatry 1975; 132: 285–7PubMedGoogle Scholar
  93. 93.
    Rich CL, Young JG, Fowler RC, et al. Guns and suicide: possible effects of some specific legislation. Am J Psychiatry 1990; 147: 342–6PubMedGoogle Scholar
  94. 94.
    Rich CL, Dhossche DM, Ghani S, et al. Suicide methods and presence of intoxicating abusable substances: some clinical and public health implications. Ann Clin Psychiatry 1998; 10: 169–75PubMedGoogle Scholar
  95. 95.
    Perlis RH, Stern TA. Suicide. In: Stern TA, Herman JB, editors. Psychiatry update and board preparation. New York: McGraw-Hill, 2000: 409–13Google Scholar
  96. 96.
    Hirschfeld RMA, Russell JM. Assessment and treatment of suicidal patients. N Engl J Med 1997; 337: 910–5PubMedCrossRefGoogle Scholar
  97. 97.
    Leenaars AA. Suicide notes: predictive clues and patterns. New York: Human Sciences Press, 1988Google Scholar
  98. 98.
    Pirkis J, Burgess P. Suicide and recency of health care contacts: a systematic review. Br J Psychiatry 1998; 173: 462–74PubMedCrossRefGoogle Scholar
  99. 99.
    Miller CL, Druss B. Suicide and access to care. Psychiatr Serv 2001; 52: 1566–7PubMedCrossRefGoogle Scholar
  100. 100.
    Andersen UA, Andersen M, Rosholm JU, et al. Contacts to the health care system prior to suicide: a comprehensive analysis using registers for general and psychiatric hospital admissions, contacts to general practitioners and practising specialists and drug prescriptions. Acta Psychiatr Scand 2000; 102: 126–34PubMedCrossRefGoogle Scholar
  101. 101.
    Franks P, Clancy CM, Marthe R. Health insurance and mortality: evidence from a national cohort. JAMA 1993; 270: 737–41PubMedCrossRefGoogle Scholar
  102. 102.
    Baker DW, Sudano JJ, Albert JM, et al. Lack of health insurance and decline in overall health in late middle age. N Engl J Med 2001; 345: 1106–12PubMedCrossRefGoogle Scholar
  103. 103.
    US Census Bureau. Statistical abstract of the United States. Washington, DC: US Government Printing Office, 2000Google Scholar
  104. 104.
    Center for Disease Control. Health statistics for the US. Atlanta (GA): US National Center for Health Statistics, 2001Google Scholar
  105. 105.
    Keller MB, Lavori PW, Klerman GL, et al. Low levels and lack of predictors of somatotherapy and psychotherapy received by depressed patients. Arch Gen Psychiatry 1986; 43: 458–66PubMedCrossRefGoogle Scholar
  106. 106.
    Isacsson G, Holmgren P, Wasserman D, et al. Use of antide-pressants among people committing suicide in Sweden. BMJ 1994; 308: 506–9PubMedCrossRefGoogle Scholar
  107. 107.
    Isacsson G. Bergman U, Rich CL. Antidepressants, depression and suicide: an analysis of the San Diego study. J Affect Disord 1994; 32: 277–86Google Scholar
  108. 108.
    Hirschfeld RM, Keller MB, Panico S, et al. The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression. JAMA 1997; 277: 333–40PubMedCrossRefGoogle Scholar
  109. 109.
    Isacsson G, Holmgren P, Druid H, et al. Psychotropics and suicide prevention: implications from toxicological screening of 5281 suicides in Sweden, 1992–1994. Br J Psychiatry 1999: 174: 259–65PubMedCrossRefGoogle Scholar
  110. 110.
    Andersen UA, Andersen M, Rosholm JU, et al. Psychopharmacological treatment and psychiatric morbidity in 390 cases of suicide with special focus on affective disorders. Acta Psychiatr Scand 2001; 104: 458–65PubMedCrossRefGoogle Scholar
  111. 111.
    Baldessarini RJ, Tondo L, Hennen J. Reduced suicide risk during long-term treatment with lithium. Ann N Y Acad Sci 2001; 932: 24–43PubMedCrossRefGoogle Scholar
  112. 112.
    Malone KM. Pharmacotherapy of affectively ill suicidal patients. Psychiatr Clin North Am 1997; 20: 613–25PubMedCrossRefGoogle Scholar
  113. 113.
    Salzman C. Treatment of the suicidal patient with psychotropic drugs and ECT. In: Jacobs DG, editor. Harvard Medical School guide to assessment and intervention in suicide. San Francisco (CA): Jossey-Bass, 1998: 372–82Google Scholar
  114. 114.
    Müller-Oerlinghausen B, Berghofer A. Antidepressants and suicidal risk. J Clin Psychiatry 1999; 60Suppl. 2: 94–9PubMedGoogle Scholar
  115. 115.
    Carlsten A, Waern M, Ekedahl A, et al. Antidepressant medication and suicide in Sweden. Pharmacoepidemiol Drug Saf 2001; 10: 525–30PubMedCrossRefGoogle Scholar
  116. 116.
    Joyce PR. Improvements in the recognition and treatment of depression and decreasing suicide rates. N Z Med J 2001; 114: 535–6PubMedGoogle Scholar
  117. 117.
    Isacsson G, Holmgren P, Druid H, et al. The utilization of antidepressants: a key issue in the prevention of suicide: an analysis of 5281 suicides in Sweden 1992–94. Acta Psychiatr Scand 1997; 96: 94–100PubMedCrossRefGoogle Scholar
  118. 118.
    Cassidy S, Henry J. Fatal toxicity of antidepressant drugs in overdose. BMJ 1987; 295: 1021–4PubMedCrossRefGoogle Scholar
  119. 119.
    Ohberg A, Vuori E, Klaukka T, et al. Antidepressants and suicide mortality. J Affect Disord 1998; 50: 225–33PubMedCrossRefGoogle Scholar
  120. 120.
    Frey R, Schreinzer D, Stimpfl T, et al. Suicide by antidepressant intoxication identified at autopsy in Vienna, 1991–1997: the favorable consequences of the increasing use of SSRIs. Eur Neuropsychopharmacol 2000; 10: 133–42PubMedCrossRefGoogle Scholar
  121. 121.
    Isacsson G, Boëthius G, Henriksson S, et al. Selective serotonin reuptake inhibitors have broadened the utilization of antidepressant treatment in accordance with recommendations: findings from a Swedish prescription database. J Affect Disord 1999; 53: 15–22PubMedCrossRefGoogle Scholar
  122. 122.
    Isacsson G. Frequency of suicides reduced with 25 percent: probably by the increased use of antidepressive agents. Lakartidningen 2000; 97: 1644–50PubMedGoogle Scholar
  123. 123.
    Rihmer Z, Belso N, Kalmár S. Antidepressants and suicide prevention in Hungary. Acta Psychiatr Scand 2001; 103: 238–9PubMedCrossRefGoogle Scholar
  124. 124.
    Murphy GE. Why women are less likely than men to commit suicide. Compr Psychiatry 1998; 39: 165–75PubMedCrossRefGoogle Scholar
  125. 125.
    Monk M. Epidemiology of suicide. Epidemiol Rev 1987; 9: 51–69PubMedGoogle Scholar
  126. 126.
    Klerman GL, Weissman MM. Increasing rate of depression. JAMA 1989; 261: 2229–35PubMedCrossRefGoogle Scholar
  127. 127.
    Clark DC, Goebel-Fabbri AE. Lifetime risk of suicide in major affective disorders. In: Jacobs DG, editor. Harvard Medical School guide to assessment and intervention in suicide. San Francisco (CA): Jossey-Bass, 1998: 270–86Google Scholar
  128. 128.
    Beasley CM, Dornseif BE, Bosomworth JC, et al. Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression. BMJ 1991; 303: 685–92PubMedCrossRefGoogle Scholar
  129. 129.
    Isacsson G, Redfors I, Wasserman D, et al. Choice of antidepressants: questionnaire survey of psychiatrists and general practitioners in two areas of Sweden. BMJ 1994; 309: 1546–9PubMedCrossRefGoogle Scholar
  130. 130.
    Jick SS, Dean AD, Jick H. Antidepressants and suicide. BMJ 1995; 310: 215–8PubMedCrossRefGoogle Scholar
  131. 131.
    Barbui C, Campomori A, D’Avanzo B, et al. Antidepressant drug use in Italy since the introduction of SSRIs: national trends, regional differences and impact on suicide rates. Soc Psychiatry Psychiatr Epidemiol 1999; 34: 152–6PubMedCrossRefGoogle Scholar
  132. 132.
    Leon AC, Keller MB, Warshaw MG, et al. Prospective study of fluoxetine treatment and suicidal behavior in affectively ill subjects. Am J Psychiatry 1999; 156: 195–201PubMedGoogle Scholar
  133. 133.
    Matthews JD, Fava M. Risk of suicidality in depression with serotonergic antidepressants. Ann Clin Psychiatry 2000; 12: 43–50PubMedGoogle Scholar
  134. 134.
    Mann JJ. Kapur S. The emergence of suicidal ideation and behavior during antidepressant pharmacotherapy. Arch Gen Psychiatry 1991; 48: 1027–33Google Scholar
  135. 135.
    Rothschild AJ, Locke CA. Re-exposure to fluoxetine after serious suicide attempts by three patients: the role of akathisia. J Clin Psychiatry 1992; 52: 491–2Google Scholar
  136. 136.
    Tollefson GD, Rampey AH, Beasley CM, et al. Absence of a relationship between adverse events and suicidality during pharmacotherapy for depression. J Clin Psychopharmacol 1994; 14: 163–9PubMedGoogle Scholar
  137. 137.
    Healy D, Langmaak C, Savage M. Suicide in the course of the treatment of depression. J Psychopharmacol 1999; 13: 94–9PubMedCrossRefGoogle Scholar
  138. 138.
    Asberg M. Neurotransmitters and suicidal behavior: evidence from cerebrospinal fluid studies. Ann N Y Acad Sci 1997; 836: 158–81PubMedCrossRefGoogle Scholar
  139. 139.
    Roy A, Nielsen D, Rylander G, et al. Genetics of suicide in depression. J Clin Psychiatry 1999; 60Suppl. 2: 12–7PubMedGoogle Scholar
  140. 140.
    van Praag HM. Serotonin disturbances and suicide risk: is aggression or anxiety the interjacent link? Crisis 2000; 21: 160–2PubMedGoogle Scholar
  141. 141.
    Mann JJ, Huang YY, Underwood MD, et al. A serotonin transporter gene promoter polymorphism (5-HTTLPR) and prefrontal cortical binding in major depression and suicide. Arch Gen Psychiatry 2000; 57: 729–38PubMedCrossRefGoogle Scholar
  142. 142.
    Mann JJ, Brent DA, Arango V. The neurobiology and genetics of suicide and attempted suicide: a focus on the serotonergic system. Neuropsychopharmacology 2001; 24: 467–77PubMedCrossRefGoogle Scholar
  143. 143.
    Jamison KR. Suicide and bipolar disorders. Ann N Y Acad Sci 1986; 487: 301–15PubMedCrossRefGoogle Scholar
  144. 144.
    Müller-Oerlinghausen B, Müser-Causemann B, Volk J. Suicides and parasuicides in a high-risk patient group on and off lithium long-term medication. J Affect Disord 1992; 25: 261–70PubMedCrossRefGoogle Scholar
  145. 145.
    Baldessarini RJ, Tondo L, Hennen J. Effects of lithium treatment and its discontinuation on suicidal behavior in bipolar manic-depressive disorders. J Clin Psychiatry 1999; 60: 77–84PubMedCrossRefGoogle Scholar
  146. 146.
    Tondo L, Hennen J, Baldessarini RJ. Reduced suicide risk with long-term lithium treatment in major affective illness: a meta-analysis. Acta Psychiatr Scand 2001; 104: 163–72PubMedCrossRefGoogle Scholar
  147. 147.
    Coppen A, Standish-Barry H, Bailey J, et al. Does lithium reduce the mortality of recurrent mood disorders? J Affect Disord 1991; 23: 1–7PubMedCrossRefGoogle Scholar
  148. 148.
    Modestin J. Schwarzenbach F. Effect of psychopharmacotherapy on suicide risk in discharged psychiatric inpatients. Acta Psychiatr Scand 1992; 85: 173–5Google Scholar
  149. 149.
    Nilsson A. Lithium therapy and suicide risk. J Clin Psychiatry 1999; 60Suppl. 2: 85–8PubMedGoogle Scholar
  150. 150.
    Schou M. Perspectives on lithium treatment of bipolar disorder: action, efficacy, effect on suicidal behavior. Bipolar Disord 1999; 1: 5–10PubMedCrossRefGoogle Scholar
  151. 151.
    Oquendo MA, Barrera A, Mann JJ. Psychopharmacological strategies for the prevention of suicidal behavior in bipolar patients. Clin Neurosci Res 2001; 1: 387–93CrossRefGoogle Scholar
  152. 152.
    Tondo L, Ghiani C, Albert M. Pharmacologic interventions in suicide prevention. J Clin Psychiatry 2001; 62Suppl. 25: 51–5PubMedGoogle Scholar
  153. 153.
    Faedda GL, Tondo L, Baldessarini RJ, et al. Outcome after rapid vs gradual discontinuation of lithium treatment in bipolar mood disorders. Arch Gen Psychiatry 1993; 50: 448–55PubMedCrossRefGoogle Scholar
  154. 154.
    Baldessarini RJ, Tondo L, Viguera AC. Effects of discontinuing lithium maintenance treatment. Bipolar Disord 1999; 1: 17–24PubMedCrossRefGoogle Scholar
  155. 155.
    Norton B. Whalley LJ. Mortality of a lithium-treated population. Br J Psychiatry 1984; 145: 277–82Google Scholar
  156. 156.
    Vestergaard P, Aagaard J. Five-year mortality in lithium-treated manic-depressive patients. J Affect Disord 1991; 21: 33–8PubMedCrossRefGoogle Scholar
  157. 157.
    Müller-Oerlinghausen B. Arguments for the specificity of the antisuicidal effect of lithium. Eur Arch Psychiatry Clin Neurosci 2001; 251Suppl. 2: 72–5CrossRefGoogle Scholar
  158. 158.
    Ahrens B, Müller-Oerlinghausen B. Does lithium exert an independent antisuicidal effect? Pharmacopsychiatry 2001; 34: 132–6PubMedCrossRefGoogle Scholar
  159. 159.
    Young LT, Warsh JJ, Kish SJ, et al. Reduced brain 5-HT and elevated NE turnover and metabolites in bipolar affective disorder. Biol Psychiatry 1994; 35: 121–7PubMedCrossRefGoogle Scholar
  160. 160.
    Wickham EA, Reed FV. Lithium for the control of aggressive and self-mutilating behavior. Int Clin Psychopharmacol 1977; 2: 181–90CrossRefGoogle Scholar
  161. 161.
    Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia. Arch Gen Psychiatry 2003; 60: 82–91PubMedCrossRefGoogle Scholar
  162. 162.
    Greil W, Kleindienst N. The comparative prophylactic efficacy of lithium and carbamazepine in patients with bipolar I disorder. Int Clin Psychopharmacol 1999; 14: 277–81PubMedGoogle Scholar
  163. 163.
    Greil W, Ludwig-Mayerhofer W, Erazo N, et al. Lithium versus carbamazepine in the maintenance treatment of bipolar disorders: a randomised study. J Affect Disord 1997; 43: 151–61PubMedCrossRefGoogle Scholar
  164. 164.
    Dardennes R, Even C, Bange F, et al. Comparison of carbamazepine and lithium in the prophylaxis of bipolar disorder: a meta-analysis. Br J Psychiatry 1995; 166: 378–81PubMedCrossRefGoogle Scholar
  165. 165.
    Denicoff KD, Smith-Jackson EE, Disney ER, et al. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J Clin Psychiatry 1997; 58: 470–8PubMedCrossRefGoogle Scholar
  166. 166.
    Goodwin FK, Fireman B, Simeon G, et al. Suicide attempts in bipolar patients on lithium vs divalproex. The 41st Annual Meeting of The American College of Neuropsychopharmacology; 2002 Dec 8–12; San Juan, Puerto RicoGoogle Scholar
  167. 167.
    Meltzer HY, Anand R, Alphs L. Reducing suicide risk in schizophrenia: focus on the role of clozapine. CNS Drugs 2000; 14: 355–65CrossRefGoogle Scholar
  168. 168.
    Wahlbeck K, Cheine M, Essali A, et al. Evidence of clozapine’s effectiveness in schizophrenia: systematic review and meta-analysis of randomized trials. Am J Psychiatry 1999; 156: 990–9PubMedGoogle Scholar
  169. 169.
    Sernyak MJ, Desai R, Stolar M, et al. Impact of clozapine on completed suicide. Am J Psychiatry 2001; 158: 931–7PubMedGoogle Scholar
  170. 170.
    Ciapparelli A, Dell’Osso L, Pini S, et al. Clozapine for treatment-refractory schizophrenia, schizoaffective disorder, and psychotic bipolar disorder: a 24-month naturalistic study. J Clin Psychiatry 2000; 61: 329–34PubMedCrossRefGoogle Scholar
  171. 171.
    Tohen M, Chengappa KN, Suppes T, et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry 2002; 59: 62–9PubMedCrossRefGoogle Scholar
  172. 172.
    Yatham LN. The role of novel antipsychotics in bipolar disorders. J Clin Psychiatry. 2002; 63Suppl. 3: 10–4PubMedGoogle Scholar
  173. 173.
    Vangala VR, Brown ES, Suppes T. Clozapine associated with decreased suicidality in bipolar disorder: a case report. Bipolar Disord 1999; 1: 123–4PubMedCrossRefGoogle Scholar
  174. 174.
    Collaborative Working Group on Clinical Trial Evaluations. Atypical antipsychotics for treatment of depression in schizophrenia and affective disorders. J Clin Psychiatry 1998; 59Suppl. 12: 41–5Google Scholar
  175. 175.
    Avery D, Winokur G. Suicide, attempted suicide, and relapse rates in depression. Arch Gen Psychiatry 1978; 35: 749–53PubMedCrossRefGoogle Scholar
  176. 176.
    Metzger ED. ECT and suicide. In: Jacobs DG, editor. Harvard Medical School guide to assessment and intervention in suicide. San Francisco (CA): Jossey-Bass, 1998: 406–14Google Scholar
  177. 177.
    Prudic J, Sackeim HA. Electroconvulsive therapy and suicide risk. J Clin Psychiatry 1999; 60Suppl. 2: 104–10PubMedGoogle Scholar
  178. 178.
    Ciapparelli A, Dell’Osso L, Tundo A, et al. Electroconvulsive therapy in medication-nonresponsive patients with mixed mania and bipolar depression. J Clin Psychiatry 2000; 62: 552–5CrossRefGoogle Scholar
  179. 179.
    Sharma V. The effect of electroconvulsive therapy on suicide risk in patients with mood disorders. Can J Psychiatry 2001; 46: 704–9PubMedGoogle Scholar
  180. 180.
    Weinger RD, editor. American Psychiatric Association Task Force on Electroconvulsive Therapy: the practice of electroconvulsive therapy: recommendations for treatment, training, and privileging. 2nd ed. Washington, DC: APA Press. 2000Google Scholar
  181. 181.
    Rose RM, Burt RA, Clayton PJ. Consensus development conference statement: electroconvulsive therapy. JAMA 1985; 254: 2103–8CrossRefGoogle Scholar
  182. 182.
    Grandin LD, Yan LJ, Gray SM, et al. Suicide prevention: increasing education and awareness. J Clin Psychiatry 2001; 62Suppl. 25: 12–6PubMedGoogle Scholar
  183. 183.
    Pearson JL, Stanley B, King CA, et al. Intervention research with persons at high risk for suicidality: safety and ethical considerations. J Clin Psychiatry 2001; 62 Suppl.25: 17–26PubMedGoogle Scholar
  184. 184.
    Gray SM, Otto MW. Psychosocial approaches to suicide prevention: applications to patients with bipolar disorder. J Clin Psychiatry 2001; 62Suppl. 25: 56–64PubMedGoogle Scholar
  185. 185.
    Taylor SJ, Kingdom D, Jenkins R. How are nations trying to prevent suicide? An analysis of national prevention strategies. Acta Psychiatr Scand 1997; 95: 45–63CrossRefGoogle Scholar
  186. 186.
    Welu TC. A follow-up program for suicide attempters: evaluation of effectiveness. Suicide Life Threat Behav 1977; 7: 17–30PubMedGoogle Scholar
  187. 187.
    Swahn MH, Potter LBS. Factors associated with the medical severity of suicide attempts in youths and young adults. Suicide Life Threat Behav 2001; 32(1 Suppl.): 21–9PubMedCrossRefGoogle Scholar
  188. 188.
    Hawton K, McKeown S, Day A, et al. Evaluation of outpatient counseling compared with general practitioner care following overdoses. Psychol Med 1987; 17: 751–61PubMedCrossRefGoogle Scholar
  189. 189.
    Salkovskis PM, Atha C, Storer D. Cognitive-behavioral problem solving in the treatment of patients who repeatedly attempt suicide: a controlled trial. Br J Psychiatry 1990; 157: 871–6PubMedCrossRefGoogle Scholar
  190. 190.
    Linehan MM, Heidi HL, Armstrong HE. Naturalistic follow-up of a behavioral treatment for chronically parasuicidal borderline patients. Arch Gen Psychiatry 1993; 50: 971–4PubMedCrossRefGoogle Scholar
  191. 191.
    McLeavey BC, Daly RJ, Ludgate JW, et al. Interpersonal problem-solving skills training in the treatment of self-poisoning patients. Suicide Life Threat Behav 1994; 24: 382–94PubMedGoogle Scholar
  192. 192.
    Egan MP. Contracting for safety: a concept analysis. Crisis 1997; 18: 17–23PubMedGoogle Scholar
  193. 193.
    Huxley NA, Parikh SV, Baldessarini RJ. Effectiveness of psychosocial treatments in bipolar disorder: state of the evidence. Harv Rev Psychiatry 2000; 8: 126-40PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2003

Authors and Affiliations

  • Leonardo Tondo
    • 1
    • 2
    Email author
  • Göran Isacsson
    • 3
  • Ross J. Baldessarini
    • 2
  1. 1.Department of PsychologyUniversity of Cagliari, Centro Lucio Bini-Stanley Medical Research Institute Research CenterCagliariItaly
  2. 2.Bipolar & Psychotic Disorders Program, Department of PsychiatryHarvard Medical School and the International Consortium for Bipolar Disorder Research, McLean Division of Massachusetts General HospitalBelmontUSA
  3. 3.Division of Psychiatry, Neurotec Institution, Karolinska InstituteHuddinge University HospitalStockholmSweden

Personalised recommendations